Varenicline Treatment in Alcohol and Nicotine Dependent Patients With Schizophrenia
Status:
Completed
Trial end date:
2011-05-01
Target enrollment:
Participant gender:
Summary
The aim of the proposed pilot study is to find out whether varenicline (ChantixTM) treatment
decreases alcohol use and smoking in patients with schizophrenia or schizoaffective disorder.
Varenicline may also improve cognition (memory and concentration) and negative symptoms (e.g.
poor attention, poverty of speech, apathy, affective flattening, anhedonia) in patients with
schizophrenia and comorbid nicotine and alcohol dependence.
Phase:
Phase 4
Details
Lead Sponsor:
State University of New York - Upstate Medical University
Collaborator:
National Alliance for Research on Schizophrenia and Depression